ABBV-2737

N/A

Report date: 2024/03/11 20:05:20
NME

Base Information

Drug NameABBV-2737
Drug Alias NameABBV-2737G-1117337GLPG-2737
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCystic fibrosis transmembrane conductance regulator modulators
TargetsCystic fibrosis transmembrane conductance regulator
Therapy Area/IndicationsPolycystic Kidney, Autosomal DominantCystic Fibrosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[12] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesGalapagos NvAbbvie Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAbbvie IncGalapagos Nv
Active IndicationsN/A
Inactive IndicationsPolycystic Kidney, Autosomal DominantCystic Fibrosis

Other Information

ATC CodeN/A
Related LinksN/A